Atopic Dermatitis News

• Arcutis Biotherapeutics' Skin Disease Cream Meets Main Goal in Late-Stage Study Arcutis Biotherapeutics said on Tuesday its skin cream met the main goal in a late-stage study for treating mild to moderate atopic dermatitis.
  Reuters Health Information, November 15, 2022
• Amazon Launches Messaged-Based Virtual Healthcare Service "Amazon Clinic is a convenient virtual care option that offers up-front pricing, and treatment within hours, instead of days," the company announced.
  WebMD Health News, November 15, 2022
• Breaking the Itch-Scratch Cycle With Mindfulness Mindful breathing can help interrupt the itch-scratch cycle in patients with dermatologic conditions, according to two physicians who spoke about the mind-body approach to pain and itch.
  MDedge News, November 14, 2022
• Serum Dupilumab Levels Do Not Predict Clinical Response in AD Researchers found no significant relationship between median week 16 dupilumab levels and 1-year clinical responses.
  MDedge News, November 11, 2022
• Monkeypox in Children Appears Rare and Relatively Mild And kids don't appear to be passing it to each other in school or daycare.
  Medscape Medical News, November 10, 2022
• Medicaid Coverage of HPV Vaccine: Implications in Dermatology Adults with dermatologic conditions such as hidradenitis suppurativa "may be at increased risk for persistent and high-risk HPV infection" and may benefit from HPV vaccination, study authors said.
  MDedge News, November 10, 2022
• Psychiatric Burden High in Cosmetic Dermatology Patients While studies have found links between the desire for cosmetic procedures and psychiatric stressors and disorders, the scarce literature on the subject mostly comes from the realm of plastic surgery.
  MDedge News, November 10, 2022
• Integrative Approach to AD Features a Long List of Options The complementary treatments for atopic dermatitis that Dr Peter Lio includes on his menu range from oral hempseed oil and topical vitamin B12 to oolong tea and acupressure.
  MDedge News, November 03, 2022
• ISAD 2022 Pediatric AD Study Compares Ciclosporin and Methotrexate The findings are important, since many regulatory bodies require patients to try first-line conventional systemic therapies before novel therapeutics, the lead investigator explained.
  Medscape Medical News, October 25, 2022
• ISAD 2022 Dupilumab-Related Ocular Disease: Unravelling the Link Ocular surface disease may be present at baseline in patients with AD treated with dupilumab.
  Medscape Medical News, October 21, 2022
• ISAD 2022 Teledermatology Assessment of Atopic Dermatitis Feasible: Study Image quality remains a challenge, according to the investigator.
  Medscape Medical News, October 21, 2022
• ISAD 2022 Study Finds Systemic AD Treatment Boosts Mood The study, which analyzed patients in a registry, found a strong correlation between depression scores and AD outcome measures.
  Medscape Medical News, October 20, 2022
• ISAD 2022 Online Support Tool Improves AD Self-Management At 24 weeks, young adults and children whose parents used the tool had improved POEM scores compared with controls.
  Medscape Medical News, October 20, 2022
• Dermatologists Call for Action in Commentary on Climate Change In the commentary, dermatologists Dr Eva Rawlings Parker and Dr Markus D. Boos urge dermatologists and their medical societies to 'engage more meaningfully' on climate change issues.
  Medscape Medical News, October 19, 2022
• ISAD 2022 Evidence Mounting That Full-Body Emollients Don't Prevent Eczema 'Did we use the wrong emollients, or did we start it too late? Or should we start facing the possibility that maybe emollients really do not prevent eczema?' the study's senior investigator asked.
  Medscape Medical News, October 19, 2022
• Isotretinoin, Methotrexate Prescribing Concerns Post-Roe v. Wade With abortion banned or greatly restricted in many states, dermatologists who prescribe isotretinoin and methotrexate said they are anxious about the future.
  Medscape Medical News, October 13, 2022
• Urticaria During Pregnancy: Study Analyzes Outcomes, Treatments The study involved 288 pregnancies in women with chronic urticaria who were part of an international, multicenter study of the Urticaria Centers of Reference and Excellence (UCARE) network.
  MDedge News, October 12, 2022
• EADV 2022 Ruxolitinib Repigments Many Vitiligo Affected Body Areas A pooled analysis of the TRuE-V1/TRuE-V2 phase 3 trials has shown that ruxolitinib (Opzelura) can help repigment the skin in multiple body areas, with lasting effects even in difficult areas.
  Medscape Medical News, October 03, 2022
• EADV 2022 Data Show Lebrikizumab Atopic Dermatitis Effects Maintained Lebrikizumab shows good long-term efficacy and reasonable safety in patients with moderate to severe atopic dermatitis according to the 52-week results from the phase 3 ADvocate1 and ADvocate2 trials.
  Medscape Medical News, September 30, 2022
• EADV 2022 BREEZE-AD-PEDS: First Data for Baricitinib in Childhood Eczema The first pediatric trial of baricitinib for childhood eczema suggests that symptoms improve, and the safety profile is similar to that seen in adults.
  Medscape Medical News, September 30, 2022